70 related articles for article (PubMed ID: 19837769)
1. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression.
Hasler G; Bonwetsch R; Giovacchini G; Toczek MT; Bagic A; Luckenbaugh DA; Drevets WC; Theodore WH
Biol Psychiatry; 2007 Dec; 62(11):1258-64. PubMed ID: 17588547
[TBL] [Abstract][Full Text] [Related]
2. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations.
Parsey RV; Ogden RT; Miller JM; Tin A; Hesselgrave N; Goldstein E; Mikhno A; Milak M; Zanderigo F; Sullivan GM; Oquendo MA; Mann JJ
Biol Psychiatry; 2010 Jul; 68(2):170-8. PubMed ID: 20497898
[TBL] [Abstract][Full Text] [Related]
3. Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality.
Miller JM; Brennan KG; Ogden TR; Oquendo MA; Sullivan GM; Mann JJ; Parsey RV
Neuropsychopharmacology; 2009 Sep; 34(10):2275-84. PubMed ID: 19458612
[TBL] [Abstract][Full Text] [Related]
4. Serotonin 1A receptors in the living brain of Alzheimer's disease patients.
Kepe V; Barrio JR; Huang SC; Ercoli L; Siddarth P; Shoghi-Jadid K; Cole GM; Satyamurthy N; Cummings JL; Small GW; Phelps ME
Proc Natl Acad Sci U S A; 2006 Jan; 103(3):702-7. PubMed ID: 16407119
[TBL] [Abstract][Full Text] [Related]
5. Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions – extending the simplified reference tissue model.
Kågedal M; Varnäs K; Hooker AC; Karlsson MO
Br J Clin Pharmacol; 2015 Jul; 80(1):116-27. PubMed ID: 25406494
[TBL] [Abstract][Full Text] [Related]
6. Application of highly sensitive UPLC-MS to determine biodistribution at tracer doses: validation with the 5-HT1A ligand [(18)F]FPWAY.
Ma Y; Lang L; Reyes L; Tokugawa J; Jagoda EM; Kiesewetter DO
Nucl Med Biol; 2009 May; 36(4):389-93. PubMed ID: 19423006
[TBL] [Abstract][Full Text] [Related]
7. Kinetic evaluation and assessment of longitudinal changes in reference region and extracerebral [
Fu JF; Lois C; Sanchez J; Becker JA; Rubinstein ZB; Thibault E; Salvatore AN; Sari H; Farrell ME; Guehl NJ; Normandin MD; Fakhri GE; Johnson KA; Price JC
J Cereb Blood Flow Metab; 2023 Apr; 43(4):581-594. PubMed ID: 36420769
[TBL] [Abstract][Full Text] [Related]
8. Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.
Svob Strac D; Pivac N; Smolders IJ; Fogel WA; De Deurwaerdere P; Di Giovanni G
Front Neurosci; 2016; 10():492. PubMed ID: 27891070
[TBL] [Abstract][Full Text] [Related]
9. 18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY.
Choi JY; Lyoo CH; Kim JS; Kim KM; Kang JH; Choi SH; Kim JJ; Ryu YH
PLoS One; 2015; 10(4):e0121342. PubMed ID: 25830772
[TBL] [Abstract][Full Text] [Related]
10. First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors.
Hillmer AT; Wooten DW; Bajwa AK; Higgins AT; Lao PJ; Betthauser TJ; Barnhart TE; Rowley HA; Stone CK; Johnson SC; Mukherjee J; Christian BT
J Nucl Med; 2014 Dec; 55(12):1973-9. PubMed ID: 25453045
[TBL] [Abstract][Full Text] [Related]
11. Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain.
Kumar JS; Parsey RV; Kassir SA; Majo VJ; Milak MS; Prabhakaran J; Simpson NR; Underwood MD; Mann JJ; Arango V
Brain Res; 2013 Apr; 1507():11-8. PubMed ID: 23454434
[TBL] [Abstract][Full Text] [Related]
12. Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history.
Gould RW; Garg PK; Garg S; Nader MA
Neuropharmacology; 2013 Jan; 64():479-88. PubMed ID: 22921923
[TBL] [Abstract][Full Text] [Related]
13. Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy.
Theodore WH; Wiggs EA; Martinez AR; Dustin IH; Khan OI; Appel S; Reeves-Tyer P; Sato S
Epilepsia; 2012 Jan; 53(1):129-33. PubMed ID: 22050514
[TBL] [Abstract][Full Text] [Related]
14. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography.
Kendziorra K; Wolf H; Meyer PM; Barthel H; Hesse S; Becker GA; Luthardt J; Schildan A; Patt M; Sorger D; Seese A; Gertz HJ; Sabri O
Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):515-25. PubMed ID: 21069319
[TBL] [Abstract][Full Text] [Related]
15. Using cerebral white matter for estimation of nondisplaceable binding of 5-HT1A receptors in temporal lobe epilepsy.
Giovacchini G; Conant S; Herscovitch P; Theodore WH
J Nucl Med; 2009 Nov; 50(11):1794-800. PubMed ID: 19837769
[TBL] [Abstract][Full Text] [Related]
16. 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction.
Giovacchini G; Toczek MT; Bonwetsch R; Bagic A; Lang L; Fraser C; Reeves-Tyer P; Herscovitch P; Eckelman WC; Carson RE; Theodore WH
J Nucl Med; 2005 Jul; 46(7):1128-35. PubMed ID: 16000281
[TBL] [Abstract][Full Text] [Related]
17. 18F-FCWAY and 18F-FDG PET in MRI-negative temporal lobe epilepsy.
Liew CJ; Lim YM; Bonwetsch R; Shamim S; Sato S; Reeves-Tyer P; Herscovitch P; Dustin I; Bagic A; Giovacchini G; Theodore WH
Epilepsia; 2009 Feb; 50(2):234-9. PubMed ID: 18801033
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy.
Toczek MT; Carson RE; Lang L; Ma Y; Spanaki MV; Der MG; Fazilat S; Kopylev L; Herscovitch P; Eckelman WC; Theodore WH
Neurology; 2003 Mar; 60(5):749-56. PubMed ID: 12629228
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
